Funding
- Private Investors
- Public FundsRetos-Colaboración 2017 CDTI 2017
- Retos-Desarrollo 2016 / 2014Innpacto 2012Torres Quevedo: 2012, 2013, 2014, 2015, 2017
- AMMIC Project / RIS3CAT 2016-2020
- RD14-1-0114 Desenvolupament MIN-102
- Innovative SME
- ENISA Jóvenes Emprendedores 2012
- TECNIOspring Industry
- Funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 822968
- NewsSee allMinoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALDMinoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s AtaxiaMinoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s AtaxiaMinoryx Therapeutics to participate in upcoming investor conferencesMinoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s AtaxiaMinoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s AtaxiaMinoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiaryMinoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s AtaxiaMinoryx Therapeutics extends its activities in BelgiumMinoryx Therapeutics announces early completion of patient randomization in the ADVANCE trial: a phase 2/3 clinical study of MIN-102 in X-ALD patients